Q-linea Ab · OMXSTO:QLINEA
Q-linea Ab — Q4 2025 Earnings Presentation
14 slides from Q-linea Ab's earnings presentation, Feb 4, 2026
Slide 1: 2025 Q4 Report
Sustainable healthcare for a new generation 2025 Q4 Report February 4th, 2025
Slide 2: Disclaimer
Disclaimer THIS PERESNTATION AND ITS CONTENTS ARE CONFIDENTIAL AND ARE NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO OR FROM THE UNITED STATES OF AMERICA, CANADA, AUSTRALIA, JAPAN OR ANY OTHER JURISDICTION WHERE SUCH DISTRIBUTION IS UNLAWFUL. T
Slide 3: Topics for today
Commercial progress update Patient impact evidence Topics for Priorities for 2026 today Financial update Respond to your questions
Slide 4: Key messages for today
Key messages for today 2025 with >400% overall revenue growth on growing installed base; 1 ~5x increase in run-rate consumables revenue Q4 2024 vs. Q4 2025 Commercial pipeline growing quickly – US expected to drive 2 growth after FDA clearance of expanded menu US market expected to jump-start from Q
Slide 5: Q-linea revolutionising AST
Q-linea revolutionising AST | Flagship ASTar platform designed to save lives Fully-automated, random 1st access platform Minutes hands-on time ~2 simple interface, load-and-go system Comprehensive menu High reproducibility Hours turn-around time ~6 High throughput with 12 samples in parallel s
Slide 6: A new standard of care
A new standard of care | Critical patient testing moving to rapid AST Clinical value Current standard of care Emerging new standard of care of information Colony-based AST Positive Blood Culture AST Whole Blood AST 5 – 7m blood infection tests Clinically- 5 – 10m critical non-blood AST urgent te
Slide 7: Pipeline progression
Pipeline progression | Long cycle times but ‘near-term’ funnel growing fast In Evaluation and/or Contracted ASTars ASTars in Clinical Use ASTar tests (‘000s) Contracting process 83 14 4.0 Evaluation 202 12 Contracting 17 56 2.8 12 38 31 1.7 7 5 1.3 4 0.9 4 2 N/A1 Q4 Q1 Q2 Q3 Q4 Q4 Q1 Q2 Q3 Q4 Q4 Q1
Slide 8: Race to breakeven
Race to breakeven | ASTar fleet expansion as visible pipeline converts ASTar units contracted for routine clinical Italy continues to drive placements use at end-of-period (>40 labs with ongoing rAST processes) 150 – 190 US acceleration in 2026 driven by v2 menu Breakeven US IDN rollouts as sy
Slide 9: Scientific leadership
Scientific leadership | Continue to ‘punch above our weight’ in the field Publications and presentations at IDWeek and IMARI Use of ‘remnant sample’ from ASTar allows for downstream workflow benefits (lower lab cost) Pooled analysis of five US sites shows high accuracy of ASTar vs. standard-of-c
Slide 10: Voice-of-customer
Voice-of-customer | Actionable diagnostic results at GWU (Washington, DC) Poster presentation made by Dr. Rebecca Yee at IMARI 2026 in Las Vegas, NV Main take-aways ASTar >36 hours faster than SoC Empiric therapy change reco- mmended in 74% of patients Clinical outcomes expected1: Reduced ex
Slide 11: Priorities for 2026
Priorities for 2026 | Accelerate from momentum build during 2025 Commercial Convert ongoing contracting discussions in US and EMEA: ‘an ASTar a week’ through 2026 priorities Support Pheno users seeking to maintain rapid AST with a superior solution First ASTar installations in Asia and Latin A
Slide 12: Financial highlights
Financial highlights | Q4 2025 REVENUES Net sales in the quarter of SEK 2.9 million, greater than full year 2024 and where we see effect on consumables sales (recurring income) driven by the installed base Net sales SEK 11.1 million for the period Jan – December 2025, approx. 370% growth over same p
Slide 13: OPEX development
OPEX development | Reducing operating costs through 2023 – 2025 Personnel expenses + Other external costs Further operating cost reduction anticipated Q1 2026 (SEK thousand) from new organisation effective Jan 1, 2026 25 000 Additional planned cost reductions during 2026, e.g., 20 000 consolidat
Slide 14: Thank you!
Thank Questions? you!